NKMAX Initiates Clinical Trial to Determine Maximum Tolerated Dose of Super NK Immuno-Oncology Drug

[Asia Economy Reporter Eunmo Koo] NKMax announced on the 28th that it will conduct an additional clinical trial in South Korea to determine the maximum tolerated dose of its SuperNK immuno-oncology drug.

This clinical trial is a Phase 1 study to confirm safety and has received approval for the clinical trial plan (IND) from the Ministry of Food and Drug Safety (MFDS). It will be conducted on six patients with advanced solid tumors who are unresponsive to existing standard anticancer drugs, administering 4 billion and 6 billion units of the SuperNK immuno-oncology drug 'SNK01' respectively, to evaluate dose-dependent safety and preliminary efficacy.

The SuperNK immune cell therapy technology developed by NKMax is NKMax's proprietary immune cell therapy technology, currently undergoing Phase 1/2a clinical trials in South Korea targeting non-small cell lung cancer patients. The Phase 1 clinical trial in the United States for refractory cancer patients and the Phase 1 clinical trial for psoriasis patients in Mexico are scheduled to announce clinical results this year.

Park Sang-woo, CEO of NKMax, stated, “We have submitted an abstract to the American Society of Clinical Oncology (ASCO) and are awaiting its acceptance to present interim results of the domestic Phase 1/2a and U.S. Phase 1 clinical trials of the SuperNK immuno-oncology drug,” adding, “We will strive to promote the excellent technology of the SuperNK immune cell therapy through continuous research and development and secure additional pipelines.”